Loading…
CelestaPro was cited for introducing unapproved and misbranded injectable botulinum toxin products into interstate commerce through its website in violation of the Federal Food, Drug, and Cosmetic Act (sections 301(a), 301(d), 503(b), and 505(a)). The company's products did not carry FDA approval or proper labeling assurances, creating risks of contamination, counterfeit formulations, inconsistent active ingredient amounts, and potentially life-threatening conditions such as sepsis from unsafe injectable administration. The FDA requested that CelestaPro immediately cease offering these unapproved and misbranded drugs for sale to U.S. consumers to protect public health.